Emiglitate

CAS : 80879-63-6

Ref. 3D-FDA87963

Informations sur le produit

• Nom: Emiglitate
• Marque: Biosynth
• Description: Emiglitate is a postprandial plasma enzyme inhibitor that has been shown to have an inhibitory effect on pancreatic enzymes. It is used as an antidiabetic agent and has been shown in clinical trials to be effective in controlling the blood glucose levels of diabetic patients. Emiglitate inhibits the activity of guanylate cyclase, which is involved in the synthesis of cyclic guanosine monophosphate (cGMP). This drug also inhibits dpp-IV, which is involved in the degradation of glucagon-like peptide-1 (GLP-1), a hormone that stimulates insulin secretion. The inhibition of GLP-1 may contribute to Emiglitate's ability to lower blood sugar levels.

Propriétés chimiques

• Masse moléculaire: 355.4 g/mol
• Formule: C₁₇H₂₅NO₇
• Degré de pureté: Min. 95%